Paper
0
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Authors
Published
Aug 5, 2015
Show more
Save
Tip0
TipSave
Abstract
Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.